Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia |
| |
| Authors: | J M Hoeg M B Maher L A Zech K R Bailey R E Gregg K J Lackner S S Fojo M A Anchors M Bojanovski D L Sprecher |
| |
| Affiliation: | 1. Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, India;2. St. Wilfred’s Institute of Pharmacy, Panvel, Mumbai, India;3. East West College of Pharmacy, Bengaluru, India;1. Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Fetscherstraße 74, Dresden 01307, Germany;2. Department of Neurology, Dresden University of Technology, Fetscherstraße 74, Dresden 01307, Germany;3. Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, Berlin 10117, Germany;1. Physics and Chemistry Department, Biomedical Research from the Center for Genetic Engineering and Biotechnology, PO Box 6162, Havana, Cuba;2. Mass Spectrometry Laboratory, Department of Proteomics, Biomedical Research from the Center for Genetic Engineering and Biotechnology, PO Box 6162, Havana, Cuba;3. Pharmaceutical Department, Biomedical Research from the Center for Genetic Engineering and Biotechnology, PO Box 6162, Havana, Cuba;4. Cuban Rheumatology Institute, Clinics and Surgery “10 de Octubre” Hospital, Calzada 10 de Octubre, # 130, e/Alejandro Ramírez y Agua Dulce, 10 de Octubre, CP10300 La Habana, Cuba;1. Department of Oral Medicine, Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-Sen University, Guangzhou, China;2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-Sen University Cancer Center, Guangzhou, China;3. School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region;1. Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA;2. Department of Radiology, Brigham and Women''s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA |
| |
| Abstract: | Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction. Mevinolin, an inhibitor of endogenous cholesterol synthesis, has been shown to reduce LDL cholesterol concentrations in a subset of type II patients with heterozygous familial hypercholesterolemia (FH). Using a double-blind, randomized, crossover, placebo-controlled trial, the safety and efficacy of mevinolin were compared in 24 patients with type II HLP with heterozygous FH (n = 6) or without FH type II HLP (n = 18). Compared with placebo treatment, both apolipoprotein B and LDL cholesterol levels were reduced (p less than 0.01) in both FH and non-FH patients by 28 to 34% with mevinolin treatment. In addition, high-density lipoprotein cholesterol levels were significantly increased (p less than 0.001) in both patients with FH (16%) and those with non-FH type II HLP (14%). Patients had no serious or clinically significant adverse effects. Thus, mevinolin is a useful drug for treatment of most patients with elevated plasma LDL cholesterol concentrations. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
